NSEShareholders meeting1d ago · 24 Sept 2026, 06:25 pm
Shareholders meeting
Bal Pharma Limited · BALPHARMA
✦ AI SummaryResults
Bal Pharma Limited has held its 39th Annual General Meeting (AGM) on September 24, 2026, through video conferencing, where the company's financial statements for the year ended March 31, 2026, were adopted, and a dividend of Rs. 1.20 per equity share was declared.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bal Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2026
Attachments (1)
📄pdf
Download →
BALPHARMA1_24092026182440_Outcome_of_AGM_Final.pdf
View document text
To To Date: September 24, 2026
Listing Compliance Department BSE Limited
National Stock Exchange of India Limited, 1st Floor, New Trading
Exchange Plaza, 5th Floor, Plot No. C/2, G Ring, Rotunda Building, P.J.
Block, Towers, Dalal Street,
Bandra Kurla Complex, Bandra (E), Mumbai – 400001
Mumbai-400051
Symbol: BALPHARMA Scrip Code: 524824
Dear Sir,
Sub: Summary of the Proceedings / Outcome of the 39th Annual General Meeting (‘AGM’)
held on 24th September 2026
Further to our letter dated August 26, 2026, sharing copy of the Notice of the 39th AGM of the
Company dated August 12, 2026, we confirm that the AGM as scheduled was held today i.e., 24th
September 2026 and the business mentioned in the said Notice were duly transacted.
In this regard, please find enclosed the proceedings as required under Regulation 30, Part A of
Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The meeting commenced at 11:30 AM (IST) and concluded at 11:55 AM (IST) (including time
allowed for e- voting at AGM).
Please take this intimation on record.
Thanking you
For Bal Pharma Limited
Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681
Enclosure: As above
To To Date: September 24, 2026
Listing Compliance Department BSE Limited
National Stock Exchange of India 1st Floor, New Trading
Limited, Ring, Rotunda Building,
Exchange Plaza, 5th Floor, Plot No. C/2, P.J. Towers, Dalal Street,
G Block, Mumbai – 400001
Bandra Kurla Complex, Bandra (E),
Mumbai-400051
Symbol: BALPHARMA S c r i p Code: 524824
Dear Sir,
Sub: Summary of the Proceedings of 39th Annual General Meeting (‘AGM’) held on
24th September 2026
In compliance with the applicable provisions of the Companies Act, 2013 and the circulars
issued by the Ministry of Corporate Affairs ("MCA") vide its Circular No.9 /2025 dated
September 22, 2025 has allowed the Companies to conduct its Annual General Meeting
through video conferencing ("VC") or other audio-visual means ("OAVM") till further
orders, in accordance with the requirements laid down in Para 3 and Para 4 of the General
Circular No. 20/2020 dated 05.05.2020 & in compliance with the applicable provisions
of the Companies Act 2013 ("Act"), and foresaid circulars and guidelines issued in this
regard, the Company has conducted the 39th Annual General Meeting (AGM) on Thursday
, the 24th day of September , 2026 at 11.30 AM through Video Conferencing/ Other Audio
Visual Means.
Directors and KMP present (all present through VC):
1. Mr. Shailesh Siroya – Managing Director
2. Mr. Ravindra Kumar Kothari – Director
3. Mr. Himesh Virupakshaya - Director
4. Mr. Jatish Sheth - Independent Director, Chairman of Audit Committee &
Nomination and Remuneration Committee.
5. Dr. Mukesh Bheekamchand - Independent Director
6. Ms. Nicola Neeladri- Independent Director
7. Mr. Bharath Bhushan D V , Chief Financial Officer
8. Mr. Shreepada M L , Company Secretary
Other Invitees in attendance (all present through VC):
1. Mr. Nikhil Kumar representing S S J N B & Co, Statutory Auditors,
2. Mr. Parameshwar G Bhat, Secretarial Auditor and also Scrutinizer for this Meeting.
3. Mr Vijayakrishna KT, Company Secretarial Adviser
Quorum of the Meeting:
58 Members were present at the meeting through video conferencing or other audio-
visual means.
Proceedings of the Meeting:
Mr. Shailesh Siroya, Managing Director of the Company, was elected as the Chairman of
the Meeting, having been proposed by Mr. Surendran V B, Member of the Company, and
seconded by Mr. Nabajit Sarma, Member of the Company.
The Chairman welcomed all the Members, Directors, Auditors and other invitees who had
joined the Meeting through VC/OAVM.
After ascertaining that the requisite quorum was present, the Chairman called the
Meeting to order. The Chairman informed the Members that the Company had taken all
feasible steps to enable the Members to participate in the AGM through VC/OAVM and to
exercise their voting rights on the businesses set out in the Notice of the AGM. Thereafter,
Mr. Shreepada M L, Company Secretary of the Company, briefed the Members regarding
the general instructions for participation in the Meeting and the procedure for casting
votes.
The Chairman then addressed the Members and briefed them on the performance of the
Company during the Financial Year 2025-26. The Chairman informed the Members that
M/s. S S J N B & Co., Chartered Accountants, Statutory Auditors, and Mr. Parameshwar G
Bhat, Practising Company Secretary, Secretarial Auditor, had expressed unmodified
opinions in their respective Audit Reports for the financial year ended March 31, 2026.
Accordingly, the Statutory Auditors’ Report and the Secretarial Audit Report were taken
as read.
The Chairman thereafter took the Notice of AGM and read out the following items of
business, as per the Notice of AGM:
No. Particulars Resolution
Type
Ordinary Business
1 To receive, consider and adopt the Audited Standalone and Ordinary
Consolidated Financial Statements of the Company for the
financial year ended March 31, 2026, together with the Reports
of the Board of Directors and the Auditors thereon.
2 To declare dividend of Rs. 1.20 per equity share of Rs. 10/- each Ordinary
for the Financial Year 2025-26.
3 To re-appoint Mr. Ravindra Kumar Kothari (DIN: 03418320), who Ordinary
retires by rotation, as a Director of the Company
Special Business
4 To ratify the remuneration payable to the Cost Auditors for the Ordinary
Financial Year 2026-27.
5 To renew the contract with M/s. Desa Marketing International. Ordinary
6 To approve the change in designation of Mr. Ravindra Kumar Special
Kothari (DIN: 03418320) from Non-Executive Director to Whole-
Time Director
7 To approve the change in designation of Mr. Virupakshaya Himesh Special
(DIN: 08554422) from Whole-Time Director to Non-Executive
Director.
The Chairman informed the Members that, as all the Resolutions had already been put to
vote through remote e-voting, there would be no proposing or seconding of the
Resolutions at the AGM and no voting by show of hands.
The Members were thereafter provided an opportunity to ask questions and express their
views through VC/OAVM. Four speaker shareholders had registered to speak; however,
none of the registered speakers addressed the Meeting.
The Chairman further informed the Members that the voting results, together with the
Scrutinizer’s Report, would be submitted to the Stock Exchanges and placed on the
Company’s website within two working days from the conclusion of the AGM, in
accordance with the applicable provisions of the Companies Act, 2013 and the SEBI
Listing Regulations.
On behalf of the Board of Directors, the Chairman thanked all the Members for their
participation in the 39th Annual General Meeting and for their continued trust and
support to Bal Pharma Limited.
There being no other business to transact, the Chairman declared the proceedings of the
39th Annual General Meeting closed.
The Meeting concluded with a vote of thanks to the Members.
The meeting commenced at 11:30 AM (IST) and concluded at 11:55 AM (IST) (including
time allowed for e- voting at AGM).
Please take this intimation on record.
Thanking you
For Bal Pharma Limited
Shailesh Siroya
Managing Director
DIN: 00048109